A first-in-human phase 1 study using this mAb has identified the doses able to fully saturate KIRs without deleterious clinical, hematological or immunological effects and has shown that a prolonged KIR blockade is safe and well tolerated in patients with CLL [255]. Here, KIR3DL1 is linked to B-cell chronic lymphocytic leukemia.